PubRank

V Bours

Author PubWeight™ 57.62‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B. Mol Cell Biol 1992 4.03
2 The candidate oncoprotein Bcl-3 is an antagonist of p50/NF-kappa B-mediated inhibition. Nature 1992 2.95
3 The oncoprotein Bcl-3 can facilitate NF-kappa B-mediated transactivation by removing inhibiting p50 homodimers from select kappa B sites. EMBO J 1993 1.61
4 The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin Genet 2010 1.58
5 Reactive oxygen intermediate-dependent NF-kappaB activation by interleukin-1beta requires 5-lipoxygenase or NADPH oxidase activity. Mol Cell Biol 1999 1.57
6 Combined suicide and cytokine gene therapy for peritoneal carcinomatosis. Gut 2000 1.39
7 NF- kappa B2/p100 induces Bcl-2 expression. Leukemia 2003 1.39
8 Highly-expressed p100/p52 (NFKB2) sequesters other NF-kappa B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 1995 1.29
9 Regulation of NF-kappaB activity by I kappaB-related proteins in adenocarcinoma cells. Oncogene 1999 1.18
10 Mutational analysis of the p50 subunit of NF-kappa B and inhibition of NF-kappa B activity by trans-dominant p50 mutants. J Virol 1993 1.14
11 Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB. Oncogene 2006 1.13
12 NF kappa B and interferon regulatory factor 1 physically interact and synergistically induce major histocompatibility class I gene expression. J Interferon Cytokine Res 1995 1.12
13 Mechanisms of persistent NF-kappa B activity in the bronchi of an animal model of asthma. J Immunol 2000 1.06
14 Multiple redox regulation in NF-kappaB transcription factor activation. Biol Chem 1997 1.04
15 CBP and histone deacetylase inhibition enhance the transactivation potential of the HOXB7 homeodomain-containing protein. Oncogene 1999 1.03
16 Distinct signal transduction pathways mediate nuclear factor-kappaB induction by IL-1beta in epithelial and lymphoid cells. J Immunol 1997 1.03
17 Correlation between nuclear factor-kappaB activity in bronchial brushing samples and lung dysfunction in an animal model of asthma. Am J Respir Crit Care Med 2000 1.02
18 Cell type-specific role for reactive oxygen species in nuclear factor-kappaB activation by interleukin-1. Biochem Pharmacol 2000 1.01
19 Retinoic acid induction of major histocompatibility complex class I genes in NTera-2 embryonal carcinoma cells involves induction of NF-kappa B (p50-p65) and retinoic acid receptor beta-retinoid X receptor beta heterodimers. Mol Cell Biol 1993 1.00
20 The homeodomain-containing proteins: an update on their interacting partners. Biochem Pharmacol 1999 0.99
21 Inhibition of the NF-kappa B transcription factor increases Bax expression in cancer cell lines. Oncogene 2001 0.96
22 Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. Oncogene 1998 0.94
23 Roles of nuclear factor-kappaB, p53, and p21/WAF1 in daunomycin-induced cell cycle arrest and apoptosis. J Pharmacol Exp Ther 2000 0.90
24 Genetic imbalances in preleukemic thymuses. Biochem Biophys Res Commun 2001 0.89
25 Stable inhibition of nuclear factor kappaB in cancer cells does not increase sensitivity to cytotoxic drugs. Cancer Res 1999 0.89
26 ATP-gated P2X1 ion channels protect against endotoxemia by dampening neutrophil activation. J Thromb Haemost 2012 0.88
27 Interleukin-1 beta induces nuclear factor kappa B in epithelial cells independently of the production of reactive oxygen intermediates. Eur J Biochem 1996 0.88
28 Pharmacological modulation of the bystander effect in the herpes simplex virus thymidine kinase/ganciclovir gene therapy system: effects of dibutyryl adenosine 3',5'-cyclic monophosphate, alpha-glycyrrhetinic acid, and cytosine arabinoside. Biochem Pharmacol 2000 0.88
29 Regulation of major histocompatibility complex class I expression by NF-kappaB-related proteins in breast cancer cells. Oncogene 1998 0.87
30 t(14;19)/BCL3 rearrangements in lymphoproliferative disorders: a review of 23 cases. Cancer Genet Cytogenet 1997 0.87
31 Role of the protein kinase C lambda/iota isoform in nuclear factor-kappaB activation by interleukin-1beta or tumor necrosis factor-alpha: cell type specificities. Biochem Pharmacol 1999 0.86
32 HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther 1997 0.85
33 IkappaB-alpha enhances transactivation by the HOXB7 homeodomain-containing protein. J Biol Chem 1999 0.85
34 Chemically selected subclones of the CEM cell line demonstrate resistance to HIV-1 infection resulting from a selective loss of NF-kappa B DNA binding proteins. J Immunol 1994 0.85
35 Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 2004 0.85
36 Impaired accumulation of granulocytes in the lung during ozone adaptation. Free Radic Biol Med 2001 0.85
37 Activation of the human immunodeficiency virus long terminal repeat by varicella-zoster virus IE4 protein requires nuclear factor-kappaB and involves both the amino-terminal and the carboxyl-terminal cysteine-rich region. J Biol Chem 1998 0.85
38 Transcription factor NF-kappa B is activated by photosensitization generating oxidative DNA damages. J Biol Chem 1995 0.84
39 Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter. Oncogene 2000 0.84
40 A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. Clin Cancer Res 1999 0.83
41 Simulation of human B-lymphocyte proliferation by AGM-1470, a potent inhibitor of angiogenesis. J Natl Cancer Inst 1995 0.83
42 Pyropheophorbide-a methyl ester-mediated photosensitization activates transcription factor NF-kappaB through the interleukin-1 receptor-dependent signaling pathway. J Biol Chem 1999 0.82
43 Rat gap junction connexin-30 inhibits proliferation of glioma cell lines. Carcinogenesis 2001 0.82
44 Molecular mechanisms involved in HIV-1 transcriptional latency and reactivation: implications for the development of therapeutic strategies. Bull Mem Acad R Med Belg 2004 0.82
45 [Hutchinson-Gilford progeria syndrome: clinical and molecular analysis in an African patient]. Rev Med Liege 2007 0.80
46 Growth regulation of astrocytes and C6 cells by TGFbeta1: correlation with gap junctions. Neuroreport 2000 0.80
47 Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis. Cancer Gene Ther 2000 0.79
48 Relationship of serum selenium levels to tumor activity in acute non-lymphocytic leukemia. Carcinogenesis 1989 0.79
49 Antitumoral vaccination with granulocyte-macrophage colony-stimulating factor or interleukin-12-expressing DHD/K12 colon adenocarcinoma cells. Cancer Gene Ther 2000 0.79
50 Deletion of Xpter encompassing the SHOX gene and PAR1 region in familial patients with Leri-Weill Dyschondrosteosis syndrome. Genet Couns 2009 0.79
51 Precocious puberty associated with partial trisomy 18q and monosomy 11q. Genet Couns 2007 0.78
52 A low rate of trisomy 21 in twin-pregnancies: a cytogenetics retrospective study of 278 cases. Genet Couns 2003 0.78
53 Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther 1998 0.78
54 [How to explore ... congenital isolated hypogonadotrophic hypogonadism]. Rev Med Liege 2010 0.77
55 Similar efficiency of DNA-liposome complexes and retrovirus-producing cells for HSV-tk suicide gene therapy of peritoneal carcinomatosis. J Drug Target 2000 0.76
56 Inositide-specific phospholipase c beta1 gene deletion is a rare event in myelodysplastic syndromes. Leukemia 2006 0.75
57 [PHARMACOGENOMICS AND PERSONALIZED MEDICINE: TOWARDS A SYSTEMATIC GENOMIC SCREENING?]. Rev Med Liege 2015 0.75
58 [Complex diseases: the importance of genetics]. Rev Med Liege 2012 0.75
59 HSV-1 thymidine kinase gene therapy for peritoneal carcinomatosis. Adv Exp Med Biol 1998 0.75
60 [Has there been progress in the treatment of metastatic pancreatic cancer?]. Rev Med Liege 2000 0.75
61 Clinical, cytogenetic and molecular characterization of two cases of mosaic ring chromosome 13. Genet Couns 2013 0.75
62 [BREAST CANCER: FROM TARGETED THERAPY TO PRECISION MEDICINE]. Rev Med Liege 2015 0.75
63 [Guidelines concerning the treatment of rectal cancer]. Rev Med Liege 2000 0.75
64 [Fish and chips]. Rev Med Liege 2010 0.75
65 [NF-kappa B and cancers]. Bull Mem Acad R Med Belg 1999 0.75
66 TNP-470, a potent angiogenesis inhibitor, amplifies human T lymphocyte activation through an induction of nuclear factor-kappaB, nuclear factor-AT, and activation protein-1 transcription factors. Lab Invest 2000 0.75
67 [Retinoids and acute promyelocytic leukemia. A therapeutic revolution]. Rev Med Liege 1996 0.75
68 [Clinical and genetic characterization of FIPA (familial isolated pituitary adenomas)]. Rev Med Liege 2009 0.75
69 [How I treat...advanced cancer of the pancreas with a novel approach directed against new targets]. Rev Med Liege 2002 0.75
70 [Hematologic cancers in 1987. Chemotherapy and immunotherapy]. Rev Med Liege 1987 0.75
71 [Bone marrow grafts: current status at the University Hospital Center in Liège]. Rev Med Liege 1990 0.75
72 [Are we genetically predisposed to addictions?]. Rev Med Liege 2013 0.75
73 [Adjuvant treatment of breast cancer: meta-analysis and therapeutic recommendations]. Rev Med Liege 2000 0.75
74 Effect of nuclear factor kappaB inhibition on tumor cell sensitivity to natural killer-mediated cytolytic function. Eur J Immunol 2001 0.75
75 [Treatment of colorectal cancer. Pharmaco-economic aspects]. Rev Med Liege 1998 0.75
76 [Malignant tumors of unknown origin]. Rev Med Liege 1999 0.75
77 [Integration of pharmacogenetics in the medical practice]. Rev Med Liege 2005 0.75
78 Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Haematologica 1999 0.75
79 [Complex diseases: from genes-environment interactions to public health issues]. Rev Med Liege 2012 0.75
80 [Molecular and genetic aspects of triple negative breast cancer and therapeutic implications]. Rev Med Liege 2011 0.75
81 [NF-kappaB: an essential signaling pathway, track for new treatments]. Bull Mem Acad R Med Belg 2005 0.75
82 [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. Rev Med Liege 1998 0.75